The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 35, Issue 11, 2005, Pages 1065-1069

  Thomson, Kirsty J ^a,c   Hart, D P ^a   Banerjee, L ^a   Ward, K N ^b   Peggs, K S ^a   Mackinnon, S ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Aciclovir; HSCT; VZV

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BUSULFAN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; FLUDARABINE; FOSCARNET; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; THIOTEPA; THYMOCYTE ANTIBODY; VALACICLOVIR; VARICELLA ZOSTER VACCINE; YTTRIUM 90;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DERMATOME; GRAFT VERSUS HOST REACTION; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LEUKEMIA; LOW DRUG DOSE; LYMPHOCYTE COUNT; LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VARICELLA ZOSTER VIRUS; VIRUS PNEUMONIA; VIRUS REACTIVATION;

ACYCLOVIR; ADULT; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CHICKENPOX; COHORT STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; T-LYMPHOCYTES; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 20044386004     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704959     Document Type: Article

References (17)

1. Arvin AM. Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000; 6: 219-230.
2. Levin MJ, Hayward AR. The varicella vaccine. Prevention of herpes zoster. Infect Dis Clin N Am 1996; 10: 657-675.
3. + T lymphocytes and epidermal cells in SCID-hu mice. J Virol 1995; 69: 5236-5242.
4. Koc Y, Miller KB, Schenkein DP et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000; 6: 44-49.
5. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985; 152: 1172-1181.
6. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13: 277-283.
7. Atkinson K, Meyers JD, Storb R et al. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980; 29: 47-50.
8. Chapman RS, Cross KW, Fleming DM. The incidence of shingles and its implications for vaccination policy. Vaccine 2003; 21: 2541-2547.
9. Kottaridis PD, Milligan DW, Chopra R et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
10. Ljungman P, Wilczek H, Gahrton G et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1986; 1: 185-192.
11. Selby PJ, Powles RL, Easton D et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989; 59: 434-438.
12. Steer CB, Szer J, Sasadeusz J et al. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplant 2000; 25: 657-664.
13. Kanda Y, Mineishi S, Saito T et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 689-692.
14. Wilson A, Sharp M, Koropchak CM et al. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis 1992; 165: 119-126.
15. Zhang Y, Cosyns M, Levin MJ, Hayward AR. Cytokine production in varicella zoster virus-stimulated limiting dilution lymphocyte cultures. Clin Exp Immunol 1994; 98: 128-133.
16. Redman RL, Nader S, Zerboni L et al. Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 1997; 176: 578-585.
17. Hata A, Asanuma H, Rinki M et al. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 2002; 347: 26-34.